Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2026)

Amylyx Pharmaceuticals' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 22627.27% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 22627.27% increase from a year earlier, with the FY2025 full-year figure at $985000.0, up 4004.17% from the prior year.
• Other Non-Current Assets improved to $2.5 million in Q1 2026 per AMLX's latest filing, from $985000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $2.5 million in Q3 2025 and bottomed at $11000.0 in Q1 2025.
• The 5-year median for Other Non-Current Assets is $493000.0 (2024), against an average of $838705.9.
• Across the five-year window, Other Non-Current Assets slumped 97.77% in 2025 and surged 22627.27% in 2026, its largest moves.
• Year by year, Other Non-Current Assets stood at $700000.0 in 2022, then gained by 0.14% to $701000.0 in 2023, then sank by 96.58% to $24000.0 in 2024, then jumped by 4004.17% to $985000.0 in 2025, then surged by 153.81% to $2.5 million in 2026.
• Per Business Quant, the three latest AMLX Other Non-Current Assets figures stand at $2.5 million (Q1 2026), $985000.0 (Q4 2025), and $2.5 million (Q3 2025).